Diamedica Therapeutics News - DMA

DiaMedica's DM-204 Selected for Late Breaking Poster Presentation at the 2012 American Heart Association's Scientific Confere...

MINNEAPOLIS, MINNESOTA--(Marketwire - Sept. 27, 2012) - DiaMedica (TSX VENTURE:DMA) today announces that it has been selected to present a Late...

DiaMedica Receives $1.7 Million Through Warrant Exercise

MINNEAPOLIS, MINNESOTA--(Marketwire - Sept. 11, 2012) - DiaMedica (TSX VENTURE:DMA) is pleased to announce that it has received gross proceeds of...

DiaMedica Retains the Law Firm Cooley LLP as its Intellectual Property and Corporate Partnering Counsel

MINNEAPOLIS, MINNESOTA--(Marketwire - Aug. 28, 2012) - DiaMedica (TSX VENTURE:DMA) today announces that it has retained Cooley LLP ("Cooley") and...

DiaMedica Accelerates Warrant Expiry Date

WINNIPEG, MANITOBA--(Marketwire - Aug. 3, 2012) - DiaMedica (TSX VENTURE:DMA) announces today that in accordance with the terms of the warrant...

DiaMedica to Present at Bloom Burton & Co. Healthcare Investor Conference

WINNIPEG, MANITOBA--(Marketwire - June 20, 2012) - DiaMedica Inc. (TSX VENTURE:DMA) - Mr. Rick Pauls, Chairman & CEO of DiaMedica, will present a...

DiaMedica Announces Summary of DM-204 Program at the 72nd Annual American Diabetes Association Conference

WINNIPEG, MANITOBA--(Marketwire - June 14, 2012) - DiaMedica Inc. (TSX VENTURE:DMA) is pleased to report the findings of a pre-clinical study...

DiaMedica's DM-204 Program Selected for Late Breaking Poster Presentation at the American Diabetes Association's 72nd Scienti...

WINNIPEG, MANITOBA--(Marketwire - June 1, 2012) - DiaMedica (TSX VENTURE:DMA) today announces that it has been selected for a Late Breaking Poster...

DiaMedica's DM-199 for Type 1 Diabetes Significantly Delays Autoimmune Attack and Demonstrates a Dramatic Increase in C-Pepti...

WINNIPEG, MANITOBA--(Marketwire - Dec. 5, 2011) - DiaMedica Inc. (TSX VENTURE:DMA) is pleased to announce new compelling Type 1 diabetes data. An...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Diamedica Therapeutics (DMA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DMA News

DiaMedica's DM-204 Selected for Late Breaking Poster Presentation at the 2012 American Heart Association's Scientific Confere...

DiaMedica Receives $1.7 Million Through Warrant Exercise

DiaMedica Retains the Law Firm Cooley LLP as its Intellectual Property and Corporate Partnering Counsel

DiaMedica Accelerates Warrant Expiry Date

DiaMedica to Present at Bloom Burton & Co. Healthcare Investor Conference

DiaMedica Announces Summary of DM-204 Program at the 72nd Annual American Diabetes Association Conference

DiaMedica's DM-204 Program Selected for Late Breaking Poster Presentation at the American Diabetes Association's 72nd Scienti...

DiaMedica Issues DSU Units and Grants Stock Options

DiaMedica Receives $3,166,800 Through Warrant Incentive Program

DiaMedica Named One of TSX Venture's Top 50 Companies

DiaMedica to Present at the 14th Annual BIO CEO and Investor Conference

DiaMedica's DM-204 for Type 2 Diabetes Successfully Humanized

DiaMedica's DM-199 for Type 1 Diabetes Significantly Delays Autoimmune Attack and Demonstrates a Dramatic Increase in C-Pepti...

DMA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Diamedica Therapeutics (DMA) News

Diamedica Therapeutics (DMA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DMA News

DiaMedica's DM-204 Selected for Late Breaking Poster Presentation at the 2012 American Heart Association's Scientific Confere...

DiaMedica Receives $1.7 Million Through Warrant Exercise

DiaMedica Retains the Law Firm Cooley LLP as its Intellectual Property and Corporate Partnering Counsel

DiaMedica Accelerates Warrant Expiry Date

DiaMedica to Present at Bloom Burton & Co. Healthcare Investor Conference

DiaMedica Announces Summary of DM-204 Program at the 72nd Annual American Diabetes Association Conference

DiaMedica's DM-204 Program Selected for Late Breaking Poster Presentation at the American Diabetes Association's 72nd Scienti...

DiaMedica Issues DSU Units and Grants Stock Options

DiaMedica Receives $3,166,800 Through Warrant Incentive Program

DiaMedica Named One of TSX Venture's Top 50 Companies

DiaMedica to Present at the 14th Annual BIO CEO and Investor Conference

DiaMedica's DM-204 for Type 2 Diabetes Successfully Humanized

DiaMedica's DM-199 for Type 1 Diabetes Significantly Delays Autoimmune Attack and Demonstrates a Dramatic Increase in C-Pepti...

DMA Discussion

Your Recent History